Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Subscribe To Our Newsletter & Stay Updated
